broncholab.com

What It Is

Broncholab is an online respiratory imaging analysis platform provided by Fluidda, designed for quantitative analysis of CT data from patients with lung conditions. Users can upload individual chest CT scan data, and the platform generates analysis results using Functional Respiratory Imaging (FRI) technology. The results are then sent to the treating physician to support the diagnosis, documentation, and follow-up of pulmonary diseases. According to the source text, the platform received FDA market clearance in March 2020 and has also received COVID-19-related authorization from Health Canada.

Core Features and Compliance

Its core capabilities focus on quantitative post-processing of chest CT scans, including 3D segmentation, subregion isolation, volume analysis, density assessment, low-density cluster analysis, fissure assessment, vascular density subrange metrics such as BV5 and BV5_10, and reporting tools. Compared with conventional pulmonary function testing, Broncholab emphasizes regional-level lung information and QCT/FRI parameters, helping physicians identify localized structural or vascular changes that may be difficult to capture with routine examinations. On data security, the text explicitly states compliance with privacy requirements, GDPR, and Belgian laws on personal data processing, while also requiring users to be responsible for the uploaded content and patient privacy compliance.

Pricing and Access Requirements

Pricing information is limited. The terms state that access to and use of the Application is free, but specific services, such as analysis reports after data upload, are charged according to a payment plan agreed between the user and Fluidda. No public packages, pay-as-you-go rates, or subscription prices are disclosed. For registration, users need to be invited by Fluidda, which suggests it is more of a controlled clinical tool for medical institutions or specialist physicians than an open self-service SaaS product.

Pros and Cons

Its strengths are its highly specialized positioning and full workflow around quantitative lung CT analysis, backed by clinical-practice credentials such as FDA clearance. For radiology and pulmonology teams, regional-level quantitative information can help with disease monitoring and treatment adjustment. The drawbacks are that public materials do not mention third-party integrations such as PACS/RIS or EHR, nor do they mention APIs, developer support, team permission management, or SLAs. Pricing is not transparent, and the availability terms explicitly do not guarantee continuous, uninterrupted access.

Who It’s For and Access from China

Broncholab is suitable for radiologists, pulmonologists, clinical research teams, and medical institutions that need quantitative follow-up of lung CT scans. The source text does not specify accessibility from China, so network connectivity, local regulatory implementation, cross-border medical data transfer, and payment methods cannot be assessed. If used in China, key considerations should include local regulations, data export requirements, and whether domestic medical imaging AI solutions or hospital PACS post-processing alternatives are available.